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Abstract
© 2018 The Cochrane Collaboration. This is a protocol for a Cochrane Review (Intervention). The
objectives are as follows: To assess the benefits and harms of noradrenaline reuptake inhibitors
(NRIs)  compared with  placebo or  no  treatment,  or  any  active  pharmacological  control  for
treating attention deficit hyperactivity disorder (ADHD) in adults.
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